Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
SCN9A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN9A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN9A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN8A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN8A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN8A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN5A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN5A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN5A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN4A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN4A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN4A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN3A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN3A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN3A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN2A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN2A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN2A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN1A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN1A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN1A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCARB2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCARB2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCARB2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCARB1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCARB1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCARB1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
S100A12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
S100A12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of S100A12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
S100A9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
S100A9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of S100A9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
S100A8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
S100A8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of S100A8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →